Axial Sulfur‐Bridged Mo‐S‐Cu Nanozymes With an Asymmetric Local Electric Field Boosting Multi‐Enzymatic Activities for Ferroptosis‐Pyroptosis Therapy
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.202523888 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Xiaoni Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals, College of Chemistry, Beijing Normal University, Beijing, P.R. China. Hauptthemen laut MEDLINE: Ferroptosis, Copper, Sulfur, Molybdenum. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
The axial coordination‐based nanozymes with asymmetric local electric field (LEF) are promising for efficient reactive oxygen species (ROS)‐mediated antitumor treatments, while normally hindered by a limited LEF upon individual coordination to adjacent atoms. Herein, an axial sulfur‐bridged Mo─S─Cu nanozymes with asymmetric LEF (A‐CuN 3 S 1 @MoS 2‐x ) was constructed based on nanoislands (NIs)‐based axial ligand‐bridging to enhance ferroptosis‐pyroptosis therapy. The S bridge between Cu atoms in CuN 3 /C nanosheets and Mo site in NIs creates a broad and enhanced LEF, which facilitates rapid electron transfer between the nanozyme and substrates, thereby regulating its enzymatic activities. Theoretical calculations reveal that the S‐bridge induces asymmetric electron‐rich redistribution along the longitudinal axis of Cu─N 3 , promoting H 2 O 2 heterolysis and O 2 desorption to enhance catalase‐like and peroxidase‐like activities. Simultaneously, Mo sites extract electrons from Cu via the S bridge, augmenting oxidase‐like activities and degrade overexpressed glutathione to avoid nontherapeutic ROS consumption. Consequently, A‐CuN 3 S 1 @MoS 2‐x induces robust ferroptosis by cytotoxic ROS accumulation and causing severe mitochondria damages, while simultaneously activating pyroptosis within the tumor region without harming normal tissues. This work demonstrates high‐efficiency ferroptosis‐pyroptosis therapy driven by multi‐enzyme catalysis via axial Mo─S─Cu coordination with an expanded asymmetric LEF, offering a novel strategy for non‐apoptotic tumor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Radiopharmaceuticals, College of Chemistry, Beijing Normal University, Beijing, P.R. China.
- State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, P.R. China.
- Department of Chemistry, College of Arts and Sciences, College of Arts and Sciences, Beijing Normal University, Zhuhai, P.R. China.
ORCID-Profile: Na Na
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, X., Ge, X., Zhao, Q., Shen, X., Li, X., Qin, J., Ouyang, J., & Na, N. (2026). Axial Sulfur‐Bridged Mo‐S‐Cu Nanozymes With an Asymmetric Local Electric Field Boosting Multi‐Enzymatic Activities for Ferroptosis‐Pyroptosis Therapy. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202523888
Vancouver
Wang X, Ge X, Zhao Q, Shen X, Li X, Qin J, et al. Axial Sulfur‐Bridged Mo‐S‐Cu Nanozymes With an Asymmetric Local Electric Field Boosting Multi‐Enzymatic Activities for Ferroptosis‐Pyroptosis Therapy. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.202523888
BibTeX
@article{Wang2026,
author = {Wang, Xiaoni and Ge, Xiyang and Zhao, Qi and Shen, Xiaotong and Li, Xiang and Qin, Jingyi and Ouyang, Jin and Na, Na},
title = {Axial Sulfur‐Bridged Mo‐S‐Cu Nanozymes With an Asymmetric Local Electric Field Boosting Multi‐Enzymatic Activities for Ferroptosis‐Pyroptosis Therapy},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.202523888}
}
EUVIMED